EMA allows emergency use of MSD's Covid-19 capsule treatment

MSD's capsule should be taken as early as possible after a Covid-19 diagnosis, within five days of symptoms beginning, the EMA instructs.

Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750

by RITZAU/AFP, translated by daniel pedersen

Published: 22.11.21 at 12:10

As Covid-19 cases soar in many places throughout Europe, the European Medicines Agency (EMA) has issued advice on Friday pertaining to the emergency use of MSD's Covid-19 capsule molnupiravir.

At the same time, the EMA announced that it was beginning a review of Pfizer's oral antiviral drug, which has received some interest recently.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.